Page 91 - BH-2-3

Brain & Heart Thrombosis, essential thrombocythemia, and recurrent stroke

of the clot. Back-to-back thrombolysis may be executable Consent for publication
within a brief gap of 16 days, even in stroke patients with
moderate-to-high NIHSS scores. Genetic tests for patients Verbal and written consent has been obtained from the
patient.
under prothrombotic state of unknown etiology and bone
marrow examination for doubtful cases should be carried Availability of data
out to provide a complete clinical picture, ensuring that a
coveted hematological disorder that might precipitate the Not applicable.
occurrence of thrombotic events is not overlooked during References
the investigation process. However, many patients are
reluctant to undertake bone marrow examination because 1. Fauchier L, Bisson A, Bodin A, et al. Ischemic stroke in
it is a painful procedure and, especially, when no new event patients with hypertrophic cardiomyopathy according
occurs after the index thrombotic event. Despite the testing to presence or absence of atrial fibrillation. Stroke.
2022;53(2):497-504.
efficacy, genetic tests are not widely available or entail
considerable costs. These limitations likely put a constraint doi: 10.1161/STROKEAHA.121.034213
in the detection of essential thrombocythemia when the 2. Pavaloiu RM, Mogoanta L. Repeated events of acute ischemic
suspected cases do not have a classical presentation. stroke in a patient with essential thrombocythemia. Curr
Health Sci J. 2017;43(1):95-97.
Acknowledgments
doi: 10.12865/CHSJ.43.01.16
We acknowledge the faith the patient and his family had on 3. Cervantes F. Management of essential thrombocythemia.
us during the difficult times. Hematology Am Soc Hematol Educ Program. 2011;2011:215-221.

Funding doi: 10.1182/asheducation-2011.1.215
4. Kahles T, Mono ML, Heldner MR, et al. Repeated intravenous
None.
thrombolysis for early recurrent stroke: Challenging the
Conflict of interest exclusion criterion. Stroke. 2016;47(8):2133-2135.
doi: 10.1161/STROKEAHA.116.013599
The authors declare that they have no competing interests.
5. Singh RJ, Chakraborty D, Dey S, et al. Intraluminal thrombi
Author contributions in the cervico-cephalic arteries. Stroke. 2019;50(2):357-364.
Conceptualization: Debabrata Chakraborty, Sadanand Dey doi: 10.1161/STROKEAHA.118.023015
Investigation: Devarati Biswas, Nirmalya Ray 6. Patel K, Mikhael E, Liu M, et al. Anticoagulation
Methodology: Sanjay Bhaumik, Devarati Biswas therapy reduces recurrent stroke in embolic stroke of
Writing – original draft: Debabrata Chakraborty, Nirmalya undetermined source patients with elevated coagulation
Ray, Devarati Biswas markers or severe left atrial enlargement. Front Neurol.
Writing – review & editing: Debabrata Chakraborty, Sanjay 2021;12:695378.
Bhaumik, Sadanand Dey doi: 10.3389/fneur.2021.695378

Ethics approval and consent to participate 7. Hasan MS, Basri HB, Hin LP, Stanslas J. Genetic
polymorphisms and drug interactions leading to clopidogrel
The Ethics committee of the Apollo Multispeciality resistance: Why the Asian population requires special
Hospitals, Kolkata, had acknowledged the verbal and attention. Int J Neurosci. 2013;123(3):143-154.
written consent obtained from the patient. doi: 10.3109/00207454.2012.744308

Volume 2 Issue 3 (2024) 5 doi: 10.36922/bh.3741